The Dance Between Tumor Molecular Biology and Antitumor Immune Response.

When the cyclin kinase 4/6 inhibitor abemaciclib was sequenced with PD-1 blockade in mostly immunologically "cold" murine models, enhanced immune-mediated antitumor effects-including increased lifespan, recruitment of CD8 cells to tumor, reduction of Treg and immunosuppressive cytokines in tumor, increased tumor antigen presentation, and broadening of the TCR repertoire-were achieved in both cutaneous and brain metastases.